Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
central nervous system
Biotech
Lilly pledges up to $237M per program in CNS genetic med collab
Lilly’s push to strengthen its genetic med offering has seen the company pledge $237 million in biobucks per program as part of the collaboration.
James Waldron
Sep 15, 2026 8:42am
Insilico’s partner pens $177M pact for ‘mass market’ CNS target
Jul 13, 2026 5:07am
BioAge CEO's big plans for 'multi-disease impact' of NLRP3 drug
May 14, 2026 11:00am
Exxel plans $13M IPO to score where other FAAH inhibitors failed
Feb 3, 2026 11:33am
Rethinking heart attacks as the nervous system gone haywire
Jan 27, 2026 11:00am
MapLight brightens SandboxAQ with CNS deal
Dec 16, 2025 7:30am
